JP2022546557A5 - - Google Patents
Info
- Publication number
- JP2022546557A5 JP2022546557A5 JP2022514209A JP2022514209A JP2022546557A5 JP 2022546557 A5 JP2022546557 A5 JP 2022546557A5 JP 2022514209 A JP2022514209 A JP 2022514209A JP 2022514209 A JP2022514209 A JP 2022514209A JP 2022546557 A5 JP2022546557 A5 JP 2022546557A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- phosphate
- group
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895417P | 2019-09-03 | 2019-09-03 | |
| US62/895,417 | 2019-09-03 | ||
| PCT/US2020/049261 WO2021046260A1 (en) | 2019-09-03 | 2020-09-03 | Asialoglycoprotein receptor mediated delivery of therapeutically active conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546557A JP2022546557A (ja) | 2022-11-04 |
| JP2022546557A5 true JP2022546557A5 (cg-RX-API-DMAC7.html) | 2023-09-13 |
| JP7672394B2 JP7672394B2 (ja) | 2025-05-07 |
Family
ID=74680487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514209A Active JP7672394B2 (ja) | 2019-09-03 | 2020-09-03 | 治療的に活性な複合体のアシアロ糖タンパク質受容体媒介送達 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12290567B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025252A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7672394B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220058578A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114929282B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020340987B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3152529A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290766B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021046260A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230227826A1 (en) * | 2020-06-18 | 2023-07-20 | Arcturus Therapeutics, Inc. | Una oligomers for the treatment of polyglutamine diseases |
| WO2021257916A1 (en) * | 2020-06-18 | 2021-12-23 | Arcturus Therapeutics, Inc. | Una oligomers for the treatment of polyglutamine diseases |
| EP4763287A2 (en) | 2021-09-03 | 2026-06-24 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CA3248209A1 (en) | 2022-05-25 | 2023-11-30 | CureVac SE | Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH) |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024104386A1 (zh) * | 2022-11-16 | 2024-05-23 | 南京明德新药研发有限公司 | 一类含七元杂环的三齿缀合基团 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| CN122121898A (zh) * | 2023-08-29 | 2026-05-29 | 甘纳合并子公司 | 聚糖缀合物组合物和方法 |
| CN117466959B (zh) * | 2023-10-30 | 2026-07-07 | 烟台药物研究所 | 一种肝靶向化合物、缀合物及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US8575123B2 (en) | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| US10023861B2 (en) | 2011-08-29 | 2018-07-17 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP4253395A3 (en) * | 2012-08-06 | 2023-11-29 | Alnylam Pharmaceuticals, Inc. | Processes for the preparation of carbohydrate conjugated rna agents |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| US9943604B2 (en) * | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
| US10358643B2 (en) * | 2014-01-30 | 2019-07-23 | Hoffmann-La Roche, Inc. | Poly oligomer compound with biocleavable conjugates |
| US10513710B2 (en) * | 2014-04-18 | 2019-12-24 | University Of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
| EP3137115B1 (en) | 2014-05-01 | 2020-10-14 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
| CR20160554A (es) * | 2014-05-01 | 2017-03-07 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor b del complemento |
| WO2015168618A2 (en) | 2014-05-01 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3865576A1 (en) | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| US9834510B2 (en) * | 2015-12-30 | 2017-12-05 | Arcturus Therapeutics, Inc. | Aromatic ionizable cationic lipid |
| JOP20170057B1 (ar) | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| EP3228326A1 (en) | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
| AU2017296195A1 (en) * | 2016-07-11 | 2019-01-24 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| WO2018067900A1 (en) | 2016-10-06 | 2018-04-12 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
| US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| CN120247964A (zh) | 2018-02-17 | 2025-07-04 | 箭头药业股份有限公司 | 三炔连接剂和使用方法 |
| WO2021257916A1 (en) * | 2020-06-18 | 2021-12-23 | Arcturus Therapeutics, Inc. | Una oligomers for the treatment of polyglutamine diseases |
| US20230227826A1 (en) * | 2020-06-18 | 2023-07-20 | Arcturus Therapeutics, Inc. | Una oligomers for the treatment of polyglutamine diseases |
-
2020
- 2020-09-03 IL IL290766A patent/IL290766B2/en unknown
- 2020-09-03 JP JP2022514209A patent/JP7672394B2/ja active Active
- 2020-09-03 WO PCT/US2020/049261 patent/WO2021046260A1/en not_active Ceased
- 2020-09-03 US US17/011,880 patent/US12290567B2/en active Active
- 2020-09-03 AU AU2020340987A patent/AU2020340987B2/en active Active
- 2020-09-03 EP EP20860366.2A patent/EP4025252A4/en active Pending
- 2020-09-03 KR KR1020227010731A patent/KR20220058578A/ko active Pending
- 2020-09-03 CN CN202080074997.9A patent/CN114929282B/zh active Active
- 2020-09-03 CA CA3152529A patent/CA3152529A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010227549B2 (en) | Pharmaceutical composition containing a drug and siRNA | |
| EP2773326B1 (en) | Method for sterilely producing lipid-nucleic acid particles | |
| ES2949172T3 (es) | Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas | |
| AU733310C (en) | High efficiency encapsulation of charged therapeutic agents in lipid vesicles | |
| JP2024533865A5 (cg-RX-API-DMAC7.html) | ||
| KR20230172570A (ko) | 양이온성 지질 및 이의 조성물 | |
| JP2017518278A5 (cg-RX-API-DMAC7.html) | ||
| WO2012024233A2 (en) | Zwitterionic lipids | |
| JP2023515218A (ja) | Pd-l1を標的とするための方法及び組成物 | |
| WO2024019770A1 (en) | Methods of making ionizable lipids and lipid nanoparticles for mrna delivery | |
| US20240175020A1 (en) | Compositions of modified trems and uses thereof | |
| US20030215489A1 (en) | Chemosensitizing with liposomes containing oligonucleotides | |
| KR20080106437A (ko) | 갈락토스 유도체, 약물 담체 및 의약 조성물 | |
| CN116615233A (zh) | 用于使生物分子在受试者中表达的系统和方法 | |
| WO2019063843A1 (en) | COMPOSITIONS AND METHODS FOR RELEASE OF MRNA IN HEPATIC CELLS | |
| US20250179492A1 (en) | Compositions of modified trems and uses thereof | |
| WO2025051994A1 (en) | Ionizable lipid nanoparticles | |
| CN120615126A (zh) | 经修饰的免疫调节剂 | |
| JP7848179B2 (ja) | リン脂質 | |
| WO1998009633A2 (en) | Pharmaceutical compositions | |
| KR20250158420A (ko) | 신규 이온화지질 및 이를 포함하는 지질나노입자 | |
| TW202523695A (zh) | 用於治療非酒精性脂肪性肝病之方法及組成物 | |
| KR20250092049A (ko) | mRNA/LNP 백신의 면역원성 향상용 지질 | |
| WO2024035952A1 (en) | Methods and compositions for modulating splicing at alternative splice sites | |
| WO2025245188A2 (en) | Methods of treating liver steatosis and non-alcoholic fatty liver disease |